fda ema ai guidelines · good ai practice
FDA-EMA Good AI Practice Guidelines in Drug Development
March 3, 2026
Updated October 15, 2026
45 min read
Explore the 2026 FDA-EMA 10 Guiding Principles of Good AI Practice in drug development. Learn about regulatory frameworks, compliance, and AI risk management.

- 01The FDA and EMA issued joint guiding principles in January 2026 to support responsible AI across drug development, manufacturing, and pharmacovigilance.
- 02The principles are high-level commitments. Applicable legal requirements must be assessed separately, and FDA's AI credibility guidance remains a nonbinding draft that is not for implementation.
- 03AI oversight should scale with context of use and model risk, supported by qualified human expertise, traceable data, performance assessment, and life cycle monitoring.
- 04ACTES reduced patient-screening time by 34% in a pediatric emergency department. This measured screening workload, rather than total enrollment duration, and preceded the joint principles.
- 05The article separates agency principles, published research, and the author's implementation suggestions. Its manufacturing and quality-control scenarios are hypothetical illustrations.
Executive Summary
The adoption of artificial intelligence (AI) technologies across the pharmaceutical product lifecycle is accelerating rapidly, promising to boost innovation and dramatically shorten drug development timelines ([1]) ([2]). However, AI’s deployment raises novel challenges for product quality, patient safety, and data integrity. In January 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issued a joint set of 10 Guiding Principles of Good AI Practice in Drug Development ([3]) ([4]). These principles – ranging from “Human-centric by design” to “Clear, essential information” – provide a high-level framework to ensure AI tools are developed and used responsibly throughout all phases of drug R&D, manufacturing, and pharmacovigilance ([5]) ([1]). This report provides a comprehensive analysis of these Guidelines in context: the historical impetus for regulating AI in medicine, the technical and ethical rationale behind each principle, and the implications for industry and regulators. We examine how these principles align with existing regulations ([6], ICH Q9, GDPR, etc.), feature case studies (e.g. AI-driven patient recruitment in clinical trials ([7]), hypothetical manufacturing applications), and survey data (e.g. Define Ventures’ July 2025 research found that 85% of surveyed leaders in its top-20 pharma subgroup viewed AI as an “immediate priority”; the research included leaders from 16 of the top 20 companies ([8])). Finally, we discuss future directions, such as anticipated guidance and harmonisation in an evolving global AI regulatory landscape.
Define Ventures: surveyed leaders in the top-20 pharma subgroup who considered AI an immediate priority
Define Ventures: pharma organizations represented in its research with formal AI governance committees
ACTES reduction in patient-screening time compared with manual screening in a pediatric emergency department
ACTES System Usability Scale score out of 100 in the pediatric emergency department study
Introduction and Background
Artificial intelligence (AI) and machine learning (ML) techniques — including deep learning, natural language processing, and predictive analytics — are increasingly being applied in pharmaceutical research and development ([1]) ([9]). These tools can generate new scientific insights from large datasets, optimize experimental design, repurpose existing drugs, and improve safety monitoring. AI-driven models have already shown promise in molecular design, patient stratification, manufacturing process control, and pharmacovigilance (post-market safety signal detection) ([1]) ([10]). For example, modern AI systems have been used to speed patient matching in clinical trials – Ni et al.’s ACTES study in a pediatric emergency department reported a 34% reduction in patient-screening time ([11]) – and to analyze real-world health records for early detection of adverse drug reactions ([12]).
Industry surveys provide evidence of this uptake. Define Ventures’ July 2025 research, based on surveys and interviews with more than 40 executives including leaders from 16 of the top 20 pharma companies, found that 85% of surveyed leaders in the top-20 subgroup considered AI an immediate priority. The report also stated that 80% of pharma organizations represented in its research had formal AI governance structures ([8]). Encouraged by AI’s potential, companies invest in diverse use cases — from medical writing and document translation to predictive modeling of clinical outcomes. Conversely, regulators and public stakeholders worry about unintended consequences: biased models, poor data practices, and opaque decision-making could jeopardize patient safety and erode trust ([13]) ([14]).
Regulators have increasingly recognized the need for guardrails on AI in healthcare. EMA’s draft “Reflection Paper” on AI in the medicinal product lifecycle outlined opportunities (e.g. reducing animal testing through predictive toxicology models) as well as challenges (e.g. algorithmic bias, technical failures) ([10]) ([13]). Similarly, in January 2025, FDA issued its first draft guidance on AI/ML in drug development, introducing a risk-based framework for assessing model credibility and emphasizing the importance of clearly defining a model’s “context-of-use” ([15]). Industry input (800+ external comments and 500 actual AI-enabled submissions since 2016 ([16])) highlighted that a one-size-fits-all approach is impractical. Instead, oversight must scale with risk: a data-mining tool in exploratory research should be evaluated less stringently than an AI system that influences dose selection or adverse event reporting ([17]) ([15]).
Against this backdrop, the FDA and EMA jointly identified ten high-level principles to harmonize international expectations for AI in drug development ([3]) ([4]). These principles are not prescriptive rules but broad commitments (“good AI practice”) that stakeholders can interpret within existing regulatory frameworks. They embody enduring values like patient welfare, scientific rigor, and accountability, as applied to AI systems. As Várhelyi emphasized, these principles represent a “first step of a renewed EU-US cooperation” in biotechnology and aim to bring both innovation and safeguards to medicine development ([18]).
This report chronicles the emergence of these principles, unpacks each one in depth, examines data and case studies on AI effectiveness and risks, compares regulatory approaches, and explores future regulatory paths. The discussion distinguishes agency principles, applicable legal requirements, published research, and the author’s implementation suggestions.
“The explanations, implementation considerations, and hypothetical examples are the author’s interpretation and practical suggestions; they are not quotations from the agencies or a new set of binding requirements.
Historical Context and Regulatory Drivers
Evolution of AI in Drug Development
Historically, drug development processes have evolved from empirical chemistry to complex biotechnology. Over the last decade, digitization and data generation (genomics, proteomics, electronic health records, etc.) have created fertile ground for AI tools. Early AI applications were limited (e.g. QSAR modeling, image analysis), but recent advances in computational power and algorithms have vastly expanded possibilities. For instance, generative models can now design novel molecules in silico, as exemplified by biotech companies like Exscientia and Insitro collaborating with major pharmas on drug discovery projects ([19]) ([20]). These partnerships underscore that cutting-edge quantitative biology (‘omics’) paired with ML can uncover subtle patterns in disease biology that manual analysis might miss ([19]).
Simultaneously, the pharmaceutical industry’s cost and time pressures (the average time to develop a new drug remains ~10-12 years) have made efficiency gains via AI highly attractive. As Insitro’s CEO remarks, ML can “unravel the underlying complexity of heterogeneous diseases” and test therapies on nuanced patient subsets that traditional methods might overlook ([21]). Companies like AstraZeneca and GSK have similarly announced broad AI initiatives across drug discovery and development stages ([2]). Real-world analytics for safety and adherence, such as AI-driven pharmacovigilance (studied in recent literature ([22])), further illustrate how AI is weaving into regulatory affairs and post-marketing surveillance.
This rapid growth, however, has outpaced formal guidance. Regulators worldwide (beyond FDA/EMA) have released general ethics guidelines for AI. Notably, the World Health Organization’s 2021 report on AI in health explicitly called for putting “ethics and human rights… at the heart of [AI’s] design, deployment and use” ([14]), echoing what would become Principle 1 of the FDA-EMA framework. In parallel, global initiatives like the EU’s AI Act (Regulation (EU) 2024/1689) and the U.S. executive orders on trustworthy AI set broad expectations for transparency, fairness, and human oversight. Yet those act at a macro level; specific guidance for AI in medicine development remained fragmented.
Precedent Food and Drug Guidelines
Before the joint principles, the FDA had begun articulating how AI should fit within existing regulatory processes. The January 2025 FDA news release ([23]) made clear this was the first agency guidance on AI in drugs. FDA Commissioner Califf highlighted a “risk-based framework… that promotes innovation and ensures…robust scientific and regulatory standards” ([24]). The release noted that FDA reviewers had already encountered AI components in over 500 submissions since 2016 ([16]), confirming AI’s ubiquity. FDA’s draft guidance laid out concepts of context-of-use and model credibility, recommending a risk-based credibility assessment for each model’s intended decision-making role ([15]). Similarly, FDA’s earlier “Good Machine Learning Practice” for medical devices (2021) had advocated for rigorous software development lifecycle and risk management for ML algorithms ([25]).
On the European side, the EMA (and its network) convened expert working groups. EMA invited consultation on its draft reflection paper ([26]); its adopted paper was subsequently published in 2024 ([27]). Its findings – that AI can aid everything from “replacing animal models” to post-marketing signal detection ([10]) – highlighted the breadth of AI applications. EMA also emphasized fundamental constraints: AI in medicines must comply with EU law and ethics (“human-centric”, respect rights) ([28]). At a joint FDA-EMA meeting in April 2024, both agencies pledged closer cooperation on novel technologies, setting the stage for the 2026 principles. (The EMA press release quoted Commissioner Várhelyi on working “together on the two sides of the Atlantic… ensuring the highest level of patient safety” ([18]).)
Other stakeholders have similarly advocated guidelines. For example, industry consortia and NGOs have produced AI governance frameworks (e.g. IBM’s AI Ethics). In pharma itself, quality and AI thought-leaders have written on best practices; a July 2024 ISPE article even laid out a detailed AI governance framework within the existing GxP QMS ([29]) ([30]). Such efforts converged on key themes (risk, transparency, interdisciplinary oversight), which the FDA-EMA collaboration distilled into the 10 Principles.
- 2021FDA device ML principles
FDA's Good Machine Learning Practice for medical devices advocated rigorous software development lifecycle and risk management for ML algorithms.
- 2024EMA adopted reflection paper
EMA published its adopted reflection paper on AI in the medicinal product lifecycle.
- Jan 2025FDA draft AI guidance
FDA issued its first draft guidance on AI/ML in drug development.
- Jan 2026Joint FDA-EMA guiding principles
FDA and EMA issued a joint set of 10 Guiding Principles of Good AI Practice in Drug Development.
The FDA-EMA Guiding Principles of Good AI Practice
The ten Guiding Principles announced in January 2026 ([5]) ([1]) are the cornerstone of this report. They are stated as high-level directives for everyone involved in medicine development – sponsors, developers, regulators, etc. – to ensure AI methods are used “safely and effectively” across the drug lifecycle ([31]). Below, each principle is examined in depth: its meaning, rationale, and key considerations for compliance, along with relevant literature and examples.
The principle summaries below are paraphrases of the joint FDA–EMA document. The explanations, implementation considerations, and hypothetical examples are the author’s interpretation and practical suggestions; they are not quotations from the agencies or a new set of binding requirements. Assess applicable statutes and regulations separately.
1. Human-Centric by Design
Principle summary (paraphrase): AI development and use should align with ethical and human-centric values. ([32]).
Explanation: This principle underscores that AI tools should ultimately serve people (patients, clinicians, scientists) and respect their rights. “Human-centric” encompasses both ethical safeguards and practical oversight. It means that AI systems should be designed from the outset to involve qualified human expertise, ensure fairness, and protect patient welfare ([14]) ([33]). Ethical values (privacy, informed consent, equity) must guide development as a default.
For example, the WHO’s “AI in Healthcare” report insisted that “only if ethics and human rights are put at the heart of [AI’s] design” can society realize AI’s benefits ([14]). Similarly, EMA’s reflection paper explicitly stated a human-centric approach, demanding compliance with ethics and fundamental rights ([28]). Practically, this means no algorithm should make critical decisions without human enquiry. Designers must build in mechanisms like human-in-the-loop (HITL): the system architecture should assume skilled professionals review and, if necessary, override AI outputs. Crucially, those humans must themselves have domain expertise. Quoting AI experts, one must ask: “if your ‘human oversight’ is someone who couldn’t do the work themselves, you haven’t met the principle” ([34]).
Rationale: Medical practice is fundamentally trust-based — patients trust clinicians, and with AI in the mix, that trust must not erode. Clear accountability is vital. “Human-centric” also implies that AI should augment human judgment, not replace it. It demands transparency: patients (and providers) should be informed when AI is used (e.g. in diagnostics or trial matching). Moreover, the principle echoes the healthcare credo “do no harm” applied to AI systems ([14]). In effect, AI developers must anticipate ethical issues like bias, and incorporate bias-mitigation strategies and audit trails.
Implementation considerations:
- Ethical review: Integrate ethical risk assessment (e.g. as part of Institutional Review Board processes) whenever AI tools are developed. Ensure patient data usage complies with privacy laws (HIPAA, GDPR) and cultural norms.
- Human oversight: Define explicitly who will review AI outputs. This should be an expert capable of independently understanding the task. Regulators have emphasized that AI systems should not autonomously drive high-stakes decisions (e.g. drug dosing) without qualified human judgement ([17]).
- Fairness and inclusivity: Check models for biases (e.g. by demographics) especially if the AI tool will impact diverse patient populations. For instance, an AI model trained only on European patient data may underperform in other ethnic groups.
- Transparency to patients: When AI systems affect patient care or safety reporting, clearly communicate their role in patient-friendly terms (see principle 10). This fosters trust and informed consent.
Example: Consider an AI algorithm that predicts which trial participants are likely to respond to a new oncology drug. A human-centric design would involve oncologists in both training and evaluating the model, and ensure that the model can explain its reasoning (e.g. highlighting key clinical factors). Patients selected by the model would still have clinicians confirm eligibility. In contrast, a purely automated “black-box” screening (with no expert review) would violate Principle 1 and Principle 4 (context of use).
2. Risk-Based Approach
Principle summary (paraphrase): Use a risk-based approach with validation, mitigation, and oversight proportionate to context of use and model risk. ([32]).
Explanation: Not all AI systems pose equal risk. This principle supports a risk classification of AI tools based on their potential impact on patient safety, product quality, and regulatory decisions. High-impact applications (e.g. AI used to adjust dosing or detect adverse events) require rigorous validation and controls, whereas low-stakes pilot or hypothesis-generating models need less stringent oversight ([17]) ([15]). The guidance explicitly states that oversight “should be proportionate to the context of use and…model risk” ([35]).
Regulatory guidance already adopts risk-based frameworks for medical devices (Class I–III, etc.) and clinical trials (minimal vs. more-than-minimal risk). Here, the idea is analogous. The FDA’s draft guidance on AI/ML in drugs defines “context of use” as how the model is used to answer a specific question and emphasizes framing model credibility requirements accordingly ([15]). In practice, an AI model that performs exploratory data mining in bioinformatics (low immediate risk) might undergo cursory checks. In contrast, an AI tool embedded in a clinical monitoring dashboard must be validated against real patient outcomes and include fail-safes.
Data/Evidence: Stakeholders have resonated with this approach. In LinkedIn commentary, AI practitioners noted that “not all AI risk is equal” and shared an experience from pharmacovigilance modeling: exploratory literature mining was “informing thinking” and errors were tolerable, but when AI was used to flag drug safety signals (which could influence patient safety), it required “stricter validation, clearer audit trails, [and] explicit human oversight” ([17]). This anecdote underlines the common-sense that AI with potential to harm patients or mislead regulators demands far more control.
Implementation considerations:
- Context-of-use definition: Before developing or validating an AI model, clearly document what decision it supports. FDA guidance treats this like a machine learning analog of a “predetermined application”—for example, “predicting tumor response in Phase II trials”.
- Model risk assessment: Convene cross-functional teams (regulatory, quality, technical) to classify the model’s risk. Consider factors such as severity of potential harm if wrong, complexity of the model, and maturity of the technology.
- Validation scope: For high-risk use-cases, perform extensive performance testing (e.g. retrospective/prospective studies, simulations under stress scenarios). For low-risk pilots, lighter-weight testing may suffice.
- Tiered governance: Align with established quality risk management (QRM) processes. For instance, the ISPE guidance on AI suggests integrating AI risk classification into ICH Q9 processes ([29]). Document decisions just as one would for any clinical system.
Example: An AI model that optimizes dosages of a precision medicine would be tagged “high risk,” triggering comprehensive validation including independent dataset testing and an on-site audit of code. By contrast, a web-based chat interface helping researchers retrieve literature citations (a lower-risk tool) might simply have routine code review and end-user feedback monitoring, with less formal validation.
3. Adherence to Standards (GxP)
Principle summary (paraphrase): Adhere to relevant legal, ethical, technical, scientific, cybersecurity, and regulatory standards, including GxP. ([32]).
Explanation: Assess the applicable standards for the particular AI use, records, and workflow. Pharmaceutical and medical-device requirements have distinct scopes. In practice, adherence spans multiple domains:
- GxP (Good Practices): Assess the relevant Good Clinical Practice (GCP) requirements for clinical-trial workflows. 21 CFR Part 11 applies to electronic records required under FDA predicate rules or submitted to FDA when electronic records are used in place of paper; the specific records and actual use determine applicability. In manufacturing, assess applicable Good Manufacturing Practice (GMP) requirements and consider Good Automated Manufacturing Practice (GAMP®) guidance as an implementation resource. For laboratory data, Good Laboratory Practice (GLP) may apply. The principle explicitly calls out “Good Practices” (GxP) ([36]). AI governance documents have noted that AI tools should be integrated into the existing Quality Management System rather than treated as exceptions ([30]).
- Data Integrity: Any data used by AI must meet integrity criteria (ALCOA+ – attributable, legible, contemporaneous, original, accurate). Determine which electronic-record and retention requirements apply before defining the pipeline’s security, version-control, and audit-trail controls ([37]).
- Cybersecurity: AI systems can be vulnerable to data breaches or adversarial attacks (e.g. maliciously altered inputs). FDA’s premarket cybersecurity guidance concerns devices with cybersecurity risk; assess its applicability before treating device-specific recommendations as requirements for a pharmaceutical AI workflow. Principle 3 specifically includes cybersecurity as a key standard ([38]).
- International Standards: Emerging standards such as ISO/IEC 42001 (AI management systems) and ISO 13485 (medical devices QMS) should inform implementation. For example, Mintanciyan et al. recommend integrating AI governance with pharmacopeial quality standards, implying use of GMP guidance (PIC/S) and even ISO standards as appropriate ([30]).
- Ethical/Legal Standards: Beyond technical, this includes legal (data privacy regulations, intellectual property rights) and ethical standards (codes of conduct, industry ethics panels).
Data/Evidence: The joint document calls for adherence to relevant standards, including GxP ([32]). Its inclusion of cybersecurity does not replace an assessment of which legal and regulatory requirements apply to the particular system.
Implementation considerations:
- Quality Systems: Explicitly incorporate AI tools into the organization’s QMS. This includes change control for AI model updates, CAPA processes for AI-related issues, and periodic review. The ISPE article suggests implementing ICH Q9 processes for AI and using the QMS framework applicable to the workflow to provide oversight ([29]) ([30]).
- Documentation: Maintain complete records of model development and operations per GxP documentation standards. This includes code repositories, data provenance logs, validation test reports, and user manuals.
- Cybersecurity Measures: Assess applicable software-security requirements and guidance before selecting controls. Perform penetration testing on AI platforms, ensure data encryption and access controls, and plan response measures for breaches.
- Third-Party Tools: If using vendor software or cloud AI platforms, verify they comply with GxP requirements. For example, cloud providers often have GxP-compliant services, but it is incumbent on sponsors to document this compliance.
Example: A machine learning model predicting drug stability might be developed in an R&D environment, but before applying it to GMP release testing, its entire workflow (data inputs, processing, model code, outputs) should be validated similarly to a conventional analytical instrument per GMP Annex 11. This ensures traceability and that any changes (e.g. model retraining) are controlled via formal change management.
4. Clear Context of Use
Principle summary (paraphrase): Define the role and scope of the AI’s intended use. ([32]).
Explanation: Context of Use (COU) is a keystone concept borrowed from regulatory science (e.g. FDA’s Biomarker COU in drug trials). In the AI domain, COU means precisely stating which decision or process the AI supports, and under what conditions. For example: “This AI model is intended to support dose selection for X drug by predicting patient clearance rates using historical pharmacokinetic data.” This statement would cover indication, population, algorithmic scope, and the decision pathway.
FDA’s statement defines context-of-use similarly as “how an AI model is used to address a certain question of interest” ([15]). Principle 4 echoes this definition. A clear COU sets boundaries so that performance claims are only made within that scope. It prevents improper extrapolation. For instance, an AI model trained on adult data may not be appropriate for pediatric use; COU must forbid such use until validated.
Rationale: Without a defined COU, it is impossible to judge whether the AI is fit for purpose. Context guides data selection, performance metrics, and risk assessment. Many AI failures in healthcare have stemmed from unresolved COU – e.g. a highly accurate pathology AI trained in one population fails in another due to unrecognized shifts. FDA describes a model’s credibility in relation to its particular COU, making a well-specified COU central to the assessment ([15]).
Implementation considerations:
- Explicit Definition: Document COU in any protocol or submission. Include who is using the AI, with what inputs, and for which decisions. If the COU changes (e.g. a model originally used for research is repurposed to production), treat it as a new COU and re-evaluate.
- Boundaries of Use: Clarify exclusions; e.g., “Do not use in populations or combination therapies that have not been studied.”
- Alignment with Validation: Ensure the validation strategy mirrors the COU. FDA advises that the tests designed to establish credibility should match the intended COU ([15]).
- Communication: Clearly state the COU to end-users. Principle 10 reinforces that users (including regulators and patients) should see what the AI is and is not intended for.
Example: Suppose an AI algorithm is employed to extract lab results from EHR notes and indicate which patients meet trial entry criteria. Its COU might be: “for identification of potential participants for Phase II oncology trials in patients aged 18-65 with specific lab ranges.” This limits application to the studied population and trial features. The algorithm documentation would meta-tag training data to resemble this COU and note that performance beyond these constraints is unverified.
5. Multidisciplinary Expertise
Principle summary (paraphrase): Integrate expertise in AI and its context of use throughout the life cycle. ([32]).
Explanation: The development and deployment of AI in drug development inherently cross multiple domains. Robust AI practice requires collaboration among subject-matter experts (e.g. clinicians, biologists, pharmacologists), data scientists, statisticians, and quality/regulatory professionals. This principle insists that such cross-functional involvement is not one-off but continuous.
For instance, domain experts should be involved in data selection (to avoid spurious features), algorithm choice (to fit scientific rationale), and interpretation of AI outputs. Data scientists, conversely, should understand clinical relevance and consider interpretability and explainability alongside predictive performance. The example from Insitro’s CEO underscores this synergy: “we’ve put in place…elements…to help people [computer scientists and life scientists] engage with each other openly…with respect.” ([20]). When neither side fully understands the other, models may be built on misleading assumptions. By contrast, “qualified SMEs using AI as a tool” exemplify the intended ideal ([39]).
Evidence: Experienced practitioners note that multidisciplinary teams materially improve AI outcomes. One LinkedIn discussion (by industry leaders) stressed that if humans overseeing AI aren’t experts in the content area, the review is meaningless. ([34]) (i.e. a non-expert cannot check nuanced medical predictions). Published guidance also reflects this: the ISPE governance article advocates forming AI governance policies that specify roles and responsibilities, and ensuring “AI-applicable technology stakeholders” are engaged across development and use ([40]).
Implementation considerations:
- Team Composition: Form an AI governance or oversight team that includes experts from necessary disciplines (e.g. quality assurance, clinical operations, IT/security). Large companies often set up AI/Data Science committees or boards.
- Ongoing Collaboration: Hold regular reviews where clinicians review AI validation results, and data scientists explain model limitations. “Handoff” should not be one-way (expert to coder) but iterative.
- Training and Culture: Invest in cross-training: for example, data scientists with pharma experience or vice versa. Encourage a “culture of respect” as Insitro did, so different experts trust and understand each other ([20]).
- Documentation of Expertise: In regulatory submissions involving AI, list team members’ qualifications. FDA often asks about team expertise for novel technologies. Showing multidisciplinary input can demonstrate diligence.
Example: Consider an AI tool designed to identify safety signals in real-world prescription data. A pharmacist/clinician would specify which adverse events and confounders matter clinically, the biostatistician would design the study of signal detection, and the ML engineer would implement the algorithm. Throughout every phase—data cleaning, model building, result interpretation—the expertise of all domains must guide decisions. If the ML engineer alone worked in isolation, the model might misinterpret patterns (e.g. a drug causing sedation vs. a drug given to already-sedated patients).
6. Data Governance and Documentation
Principle summary (paraphrase): Document data provenance, processing, and analytical decisions traceably in line with GxP, and maintain appropriate governance and sensitive-data protection. ([32]).
Explanation: AI is fundamentally data-driven, so stringent data governance is non-negotiable. This principle emphasizes two pillars:
-
Traceability and Transparency: Every dataset, transformation, and analytical step must be recorded. From raw data acquisition to final model output, there should be an “audit trail” akin to that in laboratory experiments. This includes documenting data sources, preprocessing (e.g. normalization, cleaning rules), selection criteria (inclusion/exclusion), and annotation processes. Equally, if human decisions (like labeling training data) are part of the pipeline, those must be logged too.
-
Privacy and Security: Many drug development datasets involve protected health information (PHI), proprietary research data, or patient registries. AI developers must ensure compliance with privacy laws (HIPAA, GDPR) by de-identification or controlled access. The principle explicitly highlights that “privacy and protection” of sensitive data are mandatory ([41]).
Rationale: Poor data governance can fundamentally undermine AI validity. If a model’s training data origins are opaque, users cannot judge if it was biased or incomplete. For FDA-regulated electronic records, determine which records are subject to Part 11 based on the predicate rules ([37]). A documented chain-of-custody for data eases audits and error investigations. Indeed, the ISPE article stresses data ownership, consent, and AI governance policies as essential controls ([40]).
Implementation considerations:
- Data Lineage: Use version control systems (e.g. Git) for both code and data when possible. If not, maintain a manual but standardized log of datasets and versions used to train and test models.
- Metadata Records: Employ metadata schemas to capture context (source, date, units, transformations). Data dictionaries and “data design notebooks” should accompany model documentation.
- Quality Checks: Establish data validation SOPs (completeness, consistency checks) before model training. Document how anomalies were handled. GxP guidance on data (e.g. ALCOA+) can be applied to AI data.
- Privacy Protections: For patient data, use de-identification or synthetic data where feasible. Ensure any model trained on PHI cannot inadvertently leak identifiers (re-identification risk from memorizations). Fill in consent forms that acknowledge AI usage as required.
- Documentation standards: Consider adopting FAIR data principles (Findable, Accessible, Interoperable, Reusable) as a baseline. Ensure all data pipelines are reproducible by others given the documentation.
Example: In a deep learning model trained on medical imaging scans, data governance would mean keeping a registry of each scan’s origin (site, equipment, patient cohort), any augmentations applied, and labelling by radiologists (with timestamps). If later someone queries “why did the model predict cancer here?”, one could trace back to the exact images and labels that influenced that decision. Without such traceability, any analysis of model errors would be guesswork.
7. Model Design and Development Practices
Principle summary (paraphrase): Use sound model, system, and software design with fit-for-use data, considering interpretability, explainability, and predictive performance. ([32]).
Explanation: This principle calls for disciplined, quality-focused engineering of AI systems, similar to traditional software or statistical programs under GxP. Key elements include:
- Software Engineering Discipline: Use version control, code reviews, continuous integration testing, and modular design. Incorporate known good practice guidelines such as ISPE’s GAMP® 5 for computerized systems. Treat the AI as any critical software: write specifications, document code, and version management.
- Data Fit-for-Use: Ensure training data truly represent the intended use-case. “Garbage in, garbage out” applies – biased or irrelevant data will produce unreliable models. The phrase “fit-for-use” ([42]) implies you must pre-validate that data quality (completeness, bias) matches what the model will face in practice.
- Model Transparency: Consider interpretability and explainability alongside predictive performance when choosing models; if using black-box methods, assess suitable explainability tools. For regulatory acceptance, the reasoning behind an AI’s prediction often needs to be interpretable. A model’s decision logic should be as transparent as possible to enable human review.
- Robustness and Reliability: Build the model to avoid overfitting and to handle edge cases. The principle’s emphasis on “reliability, generalisability, and robustness” ([42]) reminds us that models can degrade or fail when conditions change.
Evidence: The joint principles explicitly consider interpretability, explainability, and predictive performance together ([32]). They support sound engineering and fit-for-use data rather than a universal preference for one model family.
Implementation considerations:
- Best Practices: Adopt frameworks like GAMP® 5 Appendix O (which the ISPE article suggests for AI) ([43]). Use automated testing on each change (unit tests, performance tests). Conduct peer code reviews and maintain an issue-tracker for bugs.
- Model Development Lifecycle: Follow formal development lifecycles—planning, requirements specification, design, validation, deployment, and maintenance phases—mirroring pharmaceutical computer system validation (CSV) processes.
- Documentation: Maintain a model development report that captures algorithm choices, hyperparameters, training procedures, and version histories. For each iteration/retraining, record the changes.
- Explainability: Even if using complex models (deep neural nets, ensemble methods), implement tools (e.g. SHAP, LIME) to extract feature importances or rationale. Document these so regulators and clinicians can review why the model makes certain predictions. Simpler models (decision trees, linear models) may be preferred in high-stakes contexts for this reason.
- External Standards:ICH M11 (Clinical Electronic Structured Harmonised Protocol) provides recommendations for a harmonized digital clinical trial protocol. For AI-output records, determine applicable predicate-rule retention requirements and electronic-record controls using FDA’s Part 11 scope guidance. FDA’s cybersecurity guidance addresses devices with cybersecurity risk. For other pharmaceutical AI workflows, consider a component inventory or SBOM as a voluntary engineering practice after assessing applicable requirements.
Example: A team developing a bioinformatics ML model for toxicity prediction would start by drafting a Requirement Specification (e.g. “predict chemical AEs with >90% sensitivity for Phase I candidates”). They would maintain a Git repository; every code change triggers automated retraining and regression tests. Patient or chemical data sets would be vetted and labeled in a standardized way. If the model is a neural net, they might constrain architecture size to avoid unpredictability. And when reporting the model (e.g. to regulators), they would include training logs and use explainability graphs showing which molecular features drive decisions.
8. Risk-Based Performance Assessment
Principle summary (paraphrase): Assess the complete system, including human–AI interactions, using fit-for-use data, context-appropriate metrics, and suitable predictive-performance testing. ([32]).
Explanation: This principle addresses how AI systems are tested. It advises that evaluation should be comprehensive, not focusing solely on technical accuracy but on the overall system performance – including user interface, interpretation, and decision-making—as experienced by real users. Moreover, the evaluation must be “risk-based”: testing rigor should reflect the potential impact of errors ([44]).
A thorough performance assessment might include:
- Accuracy Metrics: Quantitative measures of model predictions (e.g. sensitivity, specificity, RMSE) that directly relate to clinical outcomes. These metrics must be chosen to align with the COU (see Principle 4). For instance, a model for drop-out prediction might use predictive value, whereas an image segmentation model might use Dice coefficient.
- System-level Testing: If the AI system requires human interaction (e.g. a decision-support dashboard), test the entire workflow. For example, simulate cases where the AI gives borderline results and observe how a clinician handles them. This may involve user studies or pilots.
- Stress & Corner Cases: Evaluate how the model behaves under extreme or unexpected inputs – e.g. very rare patient scenarios, incomplete data fields, or even adversarial perturbations. High-risk applications should have formal adversarial robustness tests.
- Calibration and Drift: Especially for predictive models (e.g. expected event incidence), perform calibration testing. After deployment, plan ongoing validation to detect performance drift as real-world data evolves.
Rationale: Traditional software verification (e.g. verification and validation in engineering) applies here but with emphasis on prediction quality. The guidance phrase “fit-for-use data and metrics” highlights that one cannot rely on generic accuracy alone. For instance, a model with 95% overall accuracy may still miss critical signals if the class distribution is skewed; thus, domain-appropriate metrics (like recall for adverse events) are needed. The inclusion of “human–AI interactions” is also key: if humans can override or interpret the AI, that mitigates risk, but if the interface is confusing, errors may increase.
Evidence: In Ni et al.’s ACTES study, an automated screening system was integrated into the clinical research coordinators’ workflow in a pediatric emergency department. Compared with manual screening, it reduced patient-screening time by 34% and achieved a System Usability Scale (SUS) score of 80.0 out of 100 ([11]). SUS scores are not satisfaction percentages ([45]). These results illustrate why workflow and usability should be measured alongside model performance; screening time is distinct from overall enrollment duration.
Implementation considerations:
- Validation Datasets: Use separate hold-out datasets and, if possible, external validation cohorts. Ensure these test datasets reflect the diversity of expected use.
- Benchmarking: Where available, compare against established methods (e.g. current manual processes) to quantify improvement or non-inferiority.
- Audit Trails: Implement automated logging of performance metrics and errors. This should feed back into periodic revalidation.
- Human Factors: Conduct usability testing. If a user interface is part of the system, apply human factors engineering principles (as in medical device software) to reduce use error.
- Regulatory Review: Prepare validation documentation (studies, protocols, results) in line with regulatory expectations. Many regulators now view robust validation as critical for AI acceptance.
Example: A predictive AI model for patient deterioration in early-phase trials might be validated retrospectively on historical trial data, showing that it would have caught 90% of serious adverse events (sensitivity metric). Then, in a prospective trial, the model is implemented in parallel with standard monitoring. Both false positive rates and clinical decision-making impacts are tracked. The validation report would describe these metrics and demonstrate that any missed events by the model were either caught by clinician override or were outside the model’s declared COU (thereby aligning with Principles 4 and 1).
9. Life Cycle Management
Principle summary (paraphrase): Use risk-based quality management throughout the life cycle, with scheduled monitoring and periodic performance re-evaluation. ([32]).
Explanation: AI systems are not static. They can degrade over time as data distributions shift (data drift), or as the operational environment changes. This principle calls for ensuring that once an AI tool is deployed, it remains under active surveillance and maintenance. Quality management (GxP-style) should extend throughout the AI’s life cycle. This includes re-assessing performance at intervals (e.g. retraining with new data if needed) and capturing issues via formal processes.
For instance, if an AI model is approved for use in production, periodic checks (monthly or quarterly) should verify that its predictive accuracy remains within bounds. If a change is observed (e.g. due to emergence of a new patient population or disease factor), the model may need retraining or escalation. The principle also suggests integrating AI into corrective and preventive action (CAPA) systems: unexpected AI outputs should trigger investigations like any other quality deviation ([29]).
Rationale: Ongoing monitoring helps teams identify performance changes and investigate issues. FDA’s Form 483 FAQ explains that a Form 483 does not constitute a final agency determination of a violation. Inspection observations should not be conflated with warning letters. The EMA/FDA principles explicitly call out data drift as a concern ([32]). As clinical practice or lab assays change, an AI model trained on old data might no longer be accurate — for example, changes in instrumentation or in disease epidemiology can alter model inputs.
Implementation considerations:
- Change Management: Treat any significant retraining or model update as a controlled change (with documentation, re-validation, and possibly regulatory notification).
- Monitoring Plans: Establish key performance indicators (KPIs) to watch over time. This could include error rates, number of overrides by users, or drift detection statistics (e.g. distribution shifts). Automated monitoring tools can flag anomalies.
- Re-Evaluation: Define triggers for re-evaluation (e.g. every 6 months, or if performance drops >10%). Reproduce initial validation studies on new data periodically.
- Archival: Store old model versions and data so one can analyze drift retrospectively if needed.
- Governance: Include AI-specific responsibilities in quality events. For example, include AI outputs in internal audits of systems, and document CAPA actions if issues arise.
Example: A pharmacovigilance AI system that auto-tags adverse event reports might be audited annually. During monitoring, the safety team notices a decline in mention recognition accuracy for a new drug formulation entry (a drift). They retrain the model with updated lexicons, document this reintegration, and validate the updated model before resuming full automation. All steps (drift detection, retraining, validation) are recorded under the computer system’s life cycle management SOPs.
10. Clear, Essential Information (Transparency)
Principle summary (paraphrase): Provide plain-language, audience-appropriate information on context of use, performance, limitations, data, updates, and interpretability or explainability. ([32]).
Explanation: Building on “human-centric” and “multidisciplinary,” this principle demands that AI systems be accompanied by straightforward explanations for stakeholders. This includes regulatory reviewers, clinicians, and even patients. Key points are:
- Performance Disclosure: Make transparent how well the AI performs (e.g. “this model correctly predicts outcome X with Y% accuracy”).
- Limitations: Clearly list what the AI cannot do or where it might fail. For instance, “not validated for patients over 80 years old,” or “may misinterpret scans if image quality is poor.”
- Data Sources: Describe the data on which the model was trained (e.g. geographic or demographic scope). This helps users assess generalizability.
- Updates: Note if and when the model was last updated or re-validated, so users know if they are using an up-to-date system.
Importantly, information must be “in plain language.” Technical jargon should be minimized or explained. For regulators and technical teams, detail is needed, but for providers and patients simpler summaries are better. The principle explicitly includes patients as an audience; for example, patients receiving treatment decisions partly informed by AI should have accessible info (this aligns with broader AI-ethics calls for explainability and consent).
Rationale: Transparency is essential for trust. Several surveys and guidelines have found that healthcare providers and patients are uneasy if AI “black boxes” make uncommunicated decisions. By making AI outputs and boundaries transparent, organizations empower informed decision-making. This principle also aligns with the FDA’s “Transparency for machine learning devices” guidance (for medical devices) which called for “comprehensive documentation” and user disclosure ([46]).
Implementation considerations:
- Model Cards and Fact Sheets: Adopt templates (e.g. “Model Card” proposals from ML research) that concisely summarize intended use, performance, and data.
- Regulatory Labeling: If the AI tool is part of a submission, include a section in the dossier describing its performance and limitations in non-technical terms.
- Patient Communication: For patient-facing AI (e.g. symptom checkers), develop user-friendly info sheets or interactive explanations.
- Feedback Mechanisms: Provide channels (e.g. helpdesk or reporting forms) for users to question AI outputs. Ensuring feedback loops is part of being transparent about uncertainty.
- Educational Training: Train healthcare staff about the AI tools they will use, so they can in turn explain basics to patients and colleagues.
Example: A hospital deploying an AI-based sepsis alert sends clinicians a one-page summary: “This system was tested on 2000 patients and has a 95% sensitivity for detecting early sepsis, but may produce false positives roughly 20% of the time. It uses blood pressure/heart rate/history data from the past 12 hours (predominantly from adults in the NE USA). It is not validated on pediatric cases.” This clear fact sheet, accompanying the AI software, exemplifies the principle.
Document who uses the AI, its inputs, and the decisions it supports.
Use cross-functional expertise to classify risk, considering potential harm, model complexity, and technology maturity.
Trace data provenance, processing, and analytical decisions, with governance and protection for sensitive data.
Use sound design and fit-for-use data, considering interpretability, explainability, and predictive performance.
Test the whole workflow when AI requires human interaction, including how clinicians handle borderline results.
Apply risk-based quality management, scheduled monitoring, and periodic performance re-evaluation throughout the life cycle.
Implementation Context and Case Studies
The 10 principles are broad guidelines. Implementing them requires integrating with existing drug development processes and quality systems. Here we explore practical applications, published research, and hypothetical illustrations. Table rows without a study citation are hypothetical examples, not documented deployments or measured results.
Examples of AI in the Drug Lifecycle
| Phase/Use Case | AI Application | Relevant Principles (examples) | Impact or Illustration |
|---|---|---|---|
| Drug Discovery (early R&D) | Target identification, molecular design, in-silico screening | #1 (ethics), #3 (adherence to standards), #4 (COU) | AI models (e.g. deep generative chemistry) designed with domain chemist input ([19]). Encourages explainability to pharma scientists and aligns with QbD. |
| Preclinical Testing | Toxicity/ADME prediction; animal replacement | #2 (risk-based), #6 (data provenance), #7 (model best practices) | In vitro/in silico toxicology models reduce animal use ([47]). Must document data sources (various assays) and validate against known cases. |
| Clinical Trial Design | Patient selection, site selection, outcome prediction | #4 (context of use), #5 (expert input), #8 (performance assessment) | In a pediatric emergency department, ACTES reduced patient-screening time by 34% compared with manual screening ([11]). This measures screening workload rather than total enrollment duration. Human oversight confirms eligibility. |
| Clinical Trial Conduct | Monitoring (e.g. vital signs anomaly detection) | #6 (data governance), #8 (performance metrics), #9 (lifecycle mgmt) | Real-time monitoring AI flags patient deterioration; sponsors use safety thresholds and periodic audits to ensure no drift in signal detection over trial. |
| Manufacturing | Process optimization, predictive maintenance | #3 (GxP adherence), #7 (software engineering), #9 (re-evaluation) | Hypothetical illustration: a soft sensor estimates blend uniformity, and controllers alert when deviations exceed defined limits. Assess applicable GMP requirements and validate the intended use. |
| Quality Control (QC) | Automated inspection (computer vision for defects) | #3 (standards), #7 (model development), #10 (transparent limits) | Hypothetical illustration: vision AI inspects tablets for cracks; QC teams document validated performance and maintain recalibration records in the QMS. |
| Regulatory Submissions (dossier prep) | Document generation/translation (LLMs) | #3 (cybersecurity/legal), #10 (info clarity), #1 (human-in-loop) | Companies experiment with AI summarizing clinical data. Outputs are double-checked by experts (embodying HITL) and note limitations (e.g. "draft content only, need human validation"). |
| Pharmacovigilance (Post-Market) | Signal detection, adverse event triage (NLP) | #5 (multidisciplinary team), #6 (privacy), #8 (risk assessment) | NLP models scan reports for keywords; a safety physician reviews AI-flagged cases nightly, ensuring patient privacy (anonymization) and verifying true signals. |
| Patient Engagement/Decision Support | Chatbots for trial info or symptom checking | #1 (ethics), #10 (accessibility), #4 (COU) | An AI chatbot answering trial FAQs is labelled as an informational tool only (explicit disclaimer) and trained to refer to human staff for medical questions. |
Table 1: Selected AI use-cases across the drug development lifecycle, illustrating how the guiding principles apply in practice.
Annotations and Data: The ACTES study provides a measured example of reduced screening workload in its pediatric emergency-department setting ([11]). The manufacturing and QC scenarios above are hypothetical illustrations; they do not establish a yield, waste, throughput, or accuracy improvement.
Real-World Example: AI in Clinical Trial Recruitment
A concrete illustration comes from Ni et al.’s 2019 evaluation of the Automated Clinical Trial Eligibility Screener (ACTES). The system was integrated into clinical research coordinators’ workflow in the pediatric emergency department at Cincinnati Children’s Hospital Medical Center. In a 12-month prospective evaluation, ACTES reduced patient-screening time by 34% compared with manual screening and achieved a System Usability Scale (SUS) score of 80.0 out of 100 ([11]). SUS is a usability score, not a satisfaction percentage ([45]).
The system recommended potential participants, and coordinators performed additional EHR screening to confirm eligibility before enrollment. This human review illustrates human expertise (Principle 5) and a defined context of use (Principle 4). It is separate from determining which electronic-record requirements apply to a particular trial workflow.
Interpretation: The study supports a screening-workload benefit in this setting. That outcome should not be presented as a general reduction in the time needed to fill trial slots or as proof that no eligible patients were missed.
Regulatory Integration: Draft Guidance and Sponsor Discussions
FDA’s January 2025 AI credibility guidance remains a draft containing nonbinding recommendations and is not for implementation. It proposes a risk-based framework for assessing model credibility in a particular context of use. FDA encourages early engagement about AI credibility assessment and use in drug development. These are recommendations; assess applicable legal requirements separately.
Hypothetical illustration: A sponsor considering an AI platform for image-based biomarker extraction to support dose selection could use the principles to organize a discussion of intended population (#4), training-data lineage (#6), predictive-performance evaluation (#8), and multidisciplinary oversight (#5). This is an implementation example, not a reported submission or FDA reviewer response.
“The study supports a screening-workload benefit in this setting. That outcome should not be presented as a general reduction in the time needed to fill trial slots or as proof that no eligible patients were missed.
Implications and Future Directions
Industry and Research Impacts
The joint principles are expected to spur both internal strategy changes within companies and technical innovation in AI. Compliance will likely involve new roles (e.g. AI Quality Lead) and processes (e.g. AI model governance boards). Define Ventures’ July 2025 research reported formal AI governance committees at 80% of pharma organizations represented in its research ([8]). This reflects the surveyed organizations, rather than a census of the industry. These committees can use the FDA–EMA principles to inform their standards while assessing applicable requirements in each jurisdiction.
For technology, the emphasis on interpretability and quality may steer R&D investment. Companies may favor “explainable AI” techniques or hybrid models combining mechanistic and data-driven methods. There is also likely to be growth in software tools that support these principles: for example, ML platforms with built-in audit logging, drift detection modules, and role-based access controls (to enforce Principle 9 and 3). Some startups are already marketing GxP-compliant AI development platforms targeted at pharma.
The principles also invite research. Academy and industry may pursue frameworks to quantify “model risk” or to certify datasets as fit-for-use. Indeed, NIST and international bodies are working on AI reliability standards that align with these ideas. Clinical researchers might study how well AI applications adhering to the principles actually perform in real trials. Policy researchers, too, will examine how inclusive and equitable the “human-centric” principle can be operationalized culturally.
Regulatory and Global Harmonization
These U.S.–EU principles provide a basis for international collaboration. EMA says they will underpin future guidance in the different jurisdictions and that additional EU guidance will take applicable legal requirements and relevant new medicines legislation into account ([48]). Guidance and binding legislation are distinct: FDA explains that guidance documents do not establish legally enforceable responsibilities ([37]). FDA’s current AI credibility document is a draft containing nonbinding recommendations and is not for implementation.
Crucially, the principles encourage interagency harmonization. Already, the FDA–EMA document explicitly aims for “enhanced international collaboration” ([49]), and other agencies (like HHS in the U.S. ([50])) are developing their own AI strategies. Despite differing legal bases, all emphasize risk governance and standards (compare FDA’s risk-based credibility ([15]), EMA’s focus on ethics ([28]), and HHS’s push for governance structures ([50])). The World Health Organization and OECD have also released AI health policies that resonate with these points. We can expect cross-references and mutual learning: e.g. FDA has collaborated with Health Canada on an AI device guidance ([46]), and could do the same for drug AI once formal guidelines appear.
Future Challenges and Opportunities
Looking ahead, new AI technologies will continually test and refine these principles. A few frontiers:
- Large Language Models (LLMs) in Medicine: The principles will need adaptation for generative AI used in writing narratives or performing literature reviews. In fact, EMA already released a “Guiding principles on large language models in regulatory science” (August 2024) covering issues like hallucinations and confidentiality. The core ideas (context, risk, human oversight) carry over, but practical guidance for LLM outputs (e.g. how to audit them) is still evolving.
- AI in Personalized Medicine: As more N-of-1 or highly individualized therapies emerge, AI models might be unique to single patients (e.g. personal cancer models). GxP adherence and data governance become tricky when “the data” is one person’s genome. Further clarity on how to scale the principles down to individual-level AI may be needed.
- Digital Twins and Virtual Trials: Complex AI simulations (“digital twins”) for organs or patient populations could revolutionize development, but raise validation complexities. Evaluating an AI that is itself a model of physiology will stretch current COU and validation norms.
- Ethical and Social Impacts: Broader issues like equitable access (will AI-approved drugs be more expensive?) and liability (who is at fault if AI yields a wrong clinical decision?) remain open. Regulators and society will have to address these under the umbrella of “human-centric” values.
In response, stakeholders should view the 10 principles as a framework that can inform future guidance. EMA anticipates additional EU guidance taking account of applicable legal requirements and relevant new EU medicines legislation ([48]). The author expects more detailed, domain-specific standards to emerge as AI use matures; the content and legal force of future instruments will need to be assessed when published.
Conclusion
The FDA–EMA Guiding Principles of Good AI Practice mark a pivotal moment in regulating pharmaceutical innovation. By articulating ten core values centered on patient welfare, risk management, scientific rigor, and transparency, these principles provide a roadmap for ethical, reliable AI integration in medicine development. They do not offer algorithmic recipes, but instead codify the spirit of best practice: that AI must be human-oriented, risk-aware, standards-abiding, and transparent.
Our analysis shows how the principles relate to existing regulatory thinking and practical experience. FDA’s 2025 draft guidance, EMA’s reflection paper, and published studies emphasize the importance of context, validation, data governance, and oversight. For example, ACTES reduced patient-screening time by 34% in a pediatric emergency department ([11]). This is a screening-workload result from a study published before the joint principles, rather than evidence that their adoption caused efficiency gains.
Looking forward, we anticipate these principles will catalyze further guidance – from formal regulatory rules to industrial standards (including ISO/IEC 42001:2023, the published AI management-system standard). They also set a precedent for international harmonization: when the U.S. and EU agree on such a framework, global stakeholders (from Japan to WHO member states) are more likely to converge on similar requirements. Ultimately, the goal is to harness AI’s transformative potential while safeguarding patient safety and product quality. The 10 Guiding Principles embody that balancing act. Through diligent application of these principles, stakeholders can ensure that AI becomes an integral and trusted part of the future of drug development.
About IntuitionLabs
Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.
IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.
AI consulting and adoption
Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.
Software, data and life-science workflows
IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.
Enterprise platforms and regulated delivery
We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.
Work with IntuitionLabs
Explore AI enablement, pharma and biotech software development, data engineering and BI, and Veeva services. Contact IntuitionLabs to discuss your workflow, information sources and implementation needs.
IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.
Sources / 50

Need Expert Guidance on This Topic?
Let's discuss how IntuitionLabs can help you navigate the challenges covered in this article.
I'm Adrien Laurent, Founder & CEO of IntuitionLabs. With 25+ years of experience in enterprise software development, I specialize in creating custom AI solutions for the pharmaceutical and life science industries.
The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein. Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document. This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it. All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders. IntuitionLabs.ai is an AI software development company specializing in helping life-science companies implement and leverage artificial intelligence solutions. Founded in 2023 by Adrien Laurent and based in San Jose, California. This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.
Related Articles

FDA AI Clinical Trials RFI: Early-Phase Response Guide
Analyze the FDA AI early-phase clinical trials RFI. This guide covers pilot program objectives, AI evaluation metrics, and evidence-based response strategies.

FDA & EMA Good AI Practice Guide for Drug Development
Examine the FDA and EMA Good AI Practice guidelines. This comprehensive implementation guide details the 10 regulatory principles for AI in drug development.

EU AI Act High-Risk Compliance: Pharma & Medical Devices
An analysis of EU AI Act high-risk compliance for pharmaceutical and medical device AI. Covers MDR/IVDR integration, data governance, and 2026 deadlines.